IP Library Granted Patent US 11,104,716
Granted Patent B2
US 11,104,716 · App. 16/749,967 · Granted Aug 31, 2021

Multimeric IL-15 soluble fusion molecules and methods of making and using same

Inventors: Hing C. Wong (Weston, FL); Peter Rhode (Miami, FL); Bai Liu (Cooper City, FL); Xiaoyun Zhu (Weston, FL); Kai-Ping Han (Weston, FL)
Assignee: Altor BioScience, LLC.
C07K14/7155A61K38/1793A61K38/2086A61K39/3955A61K45/06C07K14/5443C07K16/18C07K16/2887C12N15/09C12N15/62C12P21/00A61K38/00C07K2317/622C07K2317/732C07K2319/00C07K2319/21C07K2319/22C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,104,716
App. No.
16/749,967
Granted
Aug 31, 2021
Kind
B2
Abstract

The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).

Claims (17)

1. A method for treating human immunodeficiency virus (HIV) infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising an interleukin-15N72D:IL-15 receptor alpha Sushi/Fc (IL-15N72D:IL-15RαSu/Fc) complex, wherein the complex comprises a dimeric IL-15RαSu/Fc and two IL-15N72D molecules (ALT-803).

2. The method of claim 1 , wherein the IL-15RαSu/Fc comprises SEQ ID NO: 1.

3. The method of claim 1 , wherein a IL-15N72D molecule comprises SEQ ID NO: 2.

4. The method of claim 1 , wherein the effective amount is between about 1 and 20 μg/kg.

5. The method of claim 4 , wherein the effective amount is about 1 μg/kg.

6. The method of claim 4 , wherein the effective amount is 10 μg/week.

7. The method of claim 1 , wherein the effective amount is between about 20 μg and 100 μg/kg.

8. The method of claim 4 , wherein the effective amount is about 5 μg/kg.

9. The method of claim 4 , wherein the effective amount is about 10 μg/kg.

10. The method of claim 4 , wherein the effective amount is about 15 μg/kg.

11. The method of claim 4 , wherein the effective amount is about 20 μg/kg.

12. The method of claim 7 , wherein the effective amount is about 30 μg/kg.

13. The method of claim 7 , wherein the effective amount is about 50 μg/kg.

14. The method of claim 7 , wherein the effective amount is about 75 μg/kg.

15. The method of claim 7 , wherein the effective amount is about 100 μg/kg.

16. The method of claim 1 , wherein ALT-803 is administered once, twice, or three times per week.

17. The method of claim 1 , wherein the pharmaceutical composition is administered systemically, intravenously, or by instillation.

Assignments (3)
SECURITY INTEREST Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
MERGER Recorded Nov 18, 2020
From: ALTOR BIOSCIENCE CORPORATION
To: ALTOR BIOSCIENCE, LLC
Reel/Frame 054406/0328 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2020
From: WONG, HING C.; RHODE, PETER; LIU, BAI; ZHU, XIAOYUN; HAN, KAI-PING
To: ALTOR BIOSCIENCE CORPORATION
Reel/Frame 054381/0118 →
Cited By (5)
US 12,186,372 US 12,268,731 US 12,268,732 US 12,318,432 US 12,371,472